Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor
	Acts as a drug target< (This gene does not contain this module)

Gene: ZNF331

Summary for ZNF331

Gene information	Gene symbol	ZNF331
	Ensembl ID	ENSG00000130844
	Entrez ID	55422
	Gene name	zinc finger protein 331
	Synonyms	RITA\|ZNF361\|ZNF463
	Gene type	protein_coding
	UniProtAcc	Q9NQX6

Top

Dataset with differentially expressed gene: ZNF331

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.489027	8.53e-07
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.400138	4.89e-04
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.312785	2.10e-09
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	-0.304944	2.58e-03
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	0.559316	3.29e-17
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	0.358465	6.56e-04
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	-0.551088	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	-0.431162	1.96e-02
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	-0.536	3.69e-40
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-1.52658	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-1.76258	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.435761	4.79e-03
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.600632	1.02e-15
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	pDCs	2.33949	4.40e-05
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.517317	1.14e-13
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	1.17881	1.91e-28
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	NK cells	-0.371792	4.17e-42
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD4+ T cells	-0.264753	1.09e-09
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	-0.697051	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	-0.473728	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.478797	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	0.459315	5.18e-09
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	0.749028	7.76e-31

Top

Expression of ZNF331 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to ZNF331

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating ZNF331

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
ZNF331	hsa-miR-486-5p	97.6894	NM_001317115
ZNF331	hsa-miR-7152-5p	93.1761	NM_001317115
ZNF331	hsa-miR-4533	90.8235	NM_001317115
ZNF331	hsa-miR-380-3p	90.5351	NM_001317115
ZNF331	hsa-miR-5696	86.406	NM_001317115
ZNF331	hsa-miR-578	86.0854	NM_001317115
ZNF331	hsa-miR-6844	85.8098	NM_001079906
ZNF331	hsa-miR-196a-1-3p	85.7186	NM_001317115
ZNF331	hsa-miR-627-3p	84.3707	NM_001079906
ZNF331	hsa-miR-8070	83.8739	NM_001317115
ZNF331	hsa-miR-6864-3p	83.279	NM_001317115
ZNF331	hsa-miR-3672	83.1428	NM_001317115
ZNF331	hsa-miR-549a-5p	82.3154	NM_001317115

Page: 1

Top

Motifs and transcription factors (TFs) regulating ZNF331

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
ZNF331	dbtfbs__GMEB1_K562_ENCSR928KOR_merged_N1	GMEB1 (directAnnotation).
ZNF331	swissregulon__hs__GMEB2	GMEB2 (directAnnotation).
ZNF331	transfac_pro__M04870	HDAC2 (directAnnotation).
ZNF331	transfac_public__M00114	CREB1 (directAnnotation).
ZNF331	transfac_pro__M08187	ABL1 (directAnnotation).
ZNF331	taipale_tf_pairs__GCM1_ELF1_NRCCCRNNCGGAAGNN_CAP_repr	ELF1; GCM1 (directAnnotation).
ZNF331	transfac_pro__M06751	ZNF510 (directAnnotation).
ZNF331	transfac_pro__M06993	NFE2L3 (inferredBy_Orthology).
ZNF331	tfdimers__MD00453	ATF3; CRX (directAnnotation).
ZNF331	transfac_pro__M08803	CREM (directAnnotation).
ZNF331	transfac_pro__M00801	ATF1; ATF2; ATF3; ATF4; ATF7; CREB1; CREM (directAnnotation). ATF7-NPFF (inferredBy_Orthology).
ZNF331	tfdimers__MD00143	IKZF1; MZF1 (directAnnotation).
ZNF331	metacluster_2.7	IRF1; IRF1; IRF2; IRF2; IRF3; IRF4; IRF5; IRF6; IRF7; IRF7; IRF8; IRF8; IRF9; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; STAT1; STAT1; STAT2 (directAnnotation). PRDM1; PRDM1; PRDM1 (inferredBy_Orthology).
ZNF331	cisbp__M04023	CREB1 (directAnnotation).
ZNF331	metacluster_38.1	ETV7; ETV7; STAT1; STAT1; STAT1; STAT1; STAT1; STAT1; STAT1; STAT1; STAT1; STAT1; STAT3; STAT3; STAT3; STAT3; STAT3; STAT3; STAT3; STAT3; STAT3; STAT4; STAT5A; STAT5B (directAnnotation). STAT1; STAT3; STAT3; STAT4; STAT5A; STAT5A; STAT5B; STAT5B; STAT6; STAT6 (inferredBy_Orthology).
ZNF331	cisbp__M01816	JUN (inferredBy_Orthology).
ZNF331	swissregulon__hs__RUNX2	RUNX2 (directAnnotation).
ZNF331	metacluster_52.10	GTF3C2; ZNF436 (directAnnotation).
ZNF331	hocomoco__HSF1_HUMAN.H11MO.1.A	HSF1 (directAnnotation).
ZNF331	transfac_pro__M04706	RELA (directAnnotation).
ZNF331	transfac_pro__M05605	GATA6 (inferredBy_Orthology).
ZNF331	metacluster_8.3	BCL11A; RUNX1; RUNX1; RUNX1; RUNX1; RUNX2; RUNX2; RUNX2; RUNX2; RUNX2; RUNX2; RUNX2; RUNX2; RUNX2; RUNX3; RUNX3; RUNX3; RUNX3; RUNX3; RUNX3; RUNX3; RUNX3; RUNX3; RUNX3 (directAnnotation). CBFB; RUNX1; RUNX1; RUNX1; RUNX1; RUNX2; RUNX2; RUNX2; RUNX2; RUNX3; RUNX3; RUNX3 (inferredBy_Orthology).
ZNF331	transfac_pro__M07981	ATF3 (inferredBy_Orthology).
ZNF331	transfac_pro__M01069	GZF1 (directAnnotation).
ZNF331	c2h2_zfs__M0385	MTF1 (inferredBy_Orthology).
ZNF331	transfac_pro__M06639	ZNF559 (directAnnotation).
ZNF331	taipale_tf_pairs__ETV2_SPDEF_NSCGGACGGAWATCCGSNT_CAP	ETV2; SPDEF (directAnnotation).
ZNF331	metacluster_22.22	NFE2L2 (inferredBy_Orthology).
ZNF331	taipale_tf_pairs__TEAD4_ETV4_RCCGGAAATRCC_CAP	ETV4; TEAD4 (directAnnotation).
ZNF331	transfac_pro__M06806	PEG3 (directAnnotation).
ZNF331	transfac_pro__M00805	LEF1; TCF7; TCF7L1 (directAnnotation).
ZNF331	tfdimers__MD00165	CRX; FOS; FOSB; FOSL1; FOSL2; JUN; JUNB; JUND (directAnnotation).
ZNF331	cisbp__M00767	ZSCAN10 (inferredBy_Orthology).
ZNF331	transfac_pro__M06723	ZNF492 (directAnnotation).
ZNF331	metacluster_132.2	CTCF (directAnnotation).
ZNF331	transfac_public__M00271	RUNX1 (directAnnotation).
ZNF331	metacluster_155.19	MTF1; MTF1 (directAnnotation).
ZNF331	transfac_pro__M05803	ZNF584 (directAnnotation).
ZNF331	taipale_cyt_meth__TLX3_NAATTGNNNNNNNNNNCAATTN_FL_repr	TLX3 (directAnnotation).
ZNF331	transfac_pro__M05419	ZBTB45 (directAnnotation).
ZNF331	transfac_pro__M05935	ZNF382 (directAnnotation).
ZNF331	tfdimers__MD00158	DBP; ZNF354C (directAnnotation).
ZNF331	hdpi__RAB18	RAB18 (directAnnotation).
ZNF331	taipale_tf_pairs__ELK1_FOXI1_RSCGGAANRWMAACAN_CAP_repr	ELK1; FOXI1 (directAnnotation).
ZNF331	metacluster_38.2	STAT3 (inferredBy_Orthology).
ZNF331	metacluster_70.1	POU5F1 (directAnnotation).
ZNF331	kznf__CTCF_Rhee2011.3_ChIP-exo	CTCF (directAnnotation).
ZNF331	transfac_pro__M01250	E2F1 (directAnnotation).
ZNF331	taipale_cyt_meth__CREB1_NRTGAYGCGTN_eDBD_meth_repr	CREB1 (directAnnotation).
ZNF331	transfac_pro__M05707	ZNF239 (inferredBy_Orthology).

Page: 1 2 3 4

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

TF	motif	Expression	Cell type	Dataset	Timepoint
ZNF331	transfac_pro__M06715	up	CD4+ T cells	GSE199333	pre

Page: 1

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."